Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
DSCI [NASD]
Derma Sciences Inc.
Index- P/E- EPS (ttm)-1.36 Insider Own2.20% Shs Outstand25.25M Perf Week0.78%
Market Cap227.76M Forward P/E- EPS next Y-1.47 Insider Trans21.16% Shs Float23.82M Perf Month8.28%
Income-29.30M PEG- EPS next Q-0.43 Inst Own89.90% Short Float6.08% Perf Quarter-6.43%
Sales83.50M P/S2.73 EPS this Y-44.30% Inst Trans0.03% Short Ratio18.23 Perf Half Y-18.74%
Book/sh5.75 P/B1.57 EPS next Y8.70% ROA-23.50% Target Price16.69 Perf Year-23.17%
Cash/sh3.51 P/C2.57 EPS next 5Y- ROE-25.70% 52W Range7.88 - 15.51 Perf YTD-16.64%
Dividend- P/FCF- EPS past 5Y-11.30% ROI-31.40% 52W High-41.84% Beta1.00
Dividend %- Quick Ratio10.90 Sales past 5Y9.70% Gross Margin36.90% 52W Low14.47% ATR0.35
Employees258 Current Ratio12.90 Sales Q/Q15.50% Oper. Margin-35.80% RSI (14)57.37 Volatility2.85% 4.43%
OptionableYes Debt/Eq0.00 EPS Q/Q20.90% Profit Margin-35.10% Rel Volume1.22 Prev Close9.10
ShortableYes LT Debt/Eq0.00 EarningsAug 07 BMO Payout- Avg Volume79.49K Price9.02
Recom1.50 SMA202.76% SMA505.79% SMA200-14.45% Volume97,287 Change-0.88%
14-Aug-14Reiterated Oppenheimer Outperform $19 → $18
17-Mar-14Reiterated Oppenheimer Outperform $19 → $21
06-Jul-11Initiated Oppenheimer Outperform $21
09-Feb-11Reiterated Rodman & Renshaw Mkt Outperform $13 → $25
14-May-10Initiated Rodman & Renshaw Mkt Outperform $13
23-Oct-14 11:58AM  Derma Sciences Presented Clinical Evidence And Data On Its Tissue Regeneration Products for Diabetic Foot Ulcers At Fall 2014 Symposium On Advanced Wound Care PR Newswire
17-Oct-14 02:37PM  Derma Sciences Showcases "Off-Loading Your Diabetic Foot Ulcer, An Actor's Story," a Patient Video Featuring Actor and Director Stephen Furst and his Experience with TCC-EZ® PR Newswire
20-Aug-14 01:04PM  DERMA SCIENCES, INC. Financials EDGAR Online Financials
12-Aug-14 09:16AM  Derma Sciences to Present at Canaccord Genuity 34th Annual Growth Conference on August 14 Business Wire
07-Aug-14 11:00AM  Derma Sciences Inc Earnings Call scheduled for 11:00 am ET today CCBN -7.20%
07:30AM  Derma Sciences Reports Second Quarter Financial Results Business Wire
07:07AM  Q2 2014 Derma Sciences, Inc. Earnings Release - Before Market Open CCBN
06-Aug-14 05:09PM  DERMA SCIENCES, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
01-Aug-14 07:30AM  Derma Sciences to Hold Second Quarter Financial Results Conference Call on August 7th Business Wire
25-Jul-14 07:30AM  Derma Sciences CEO Discusses Continued Growth of MEDIHONEY® at Comvita Annual Meeting of Shareholders Business Wire
22-Jul-14 09:02AM  Derma Sciences announces Veterans Administration adds AMNIOEXCEL® to its Federal Supply Schedule Business Wire
19-Jun-14 07:47AM  Derma (DSCI) is in Overbought Territory: What's Next? Zacks
13-Jun-14 03:59PM  Derma Sciences, Inc. to Webcast June 17th Analyst Day Business Wire
29-May-14 09:00PM  [video] Derma Sciences CEO: Medihoney Sales Sweet and Getting Sweeter at TheStreet
23-May-14 04:50PM  DERMA SCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote o EDGAR Online
22-May-14 11:10AM  Derma Sciences management to meet with Oppenheimer at theflyonthewall.com
09-May-14 07:39PM  Derma Sciences' (DSCI) CEO Ed Quilty on Q1 2014 Results - Earnings Call Transcript at Seeking Alpha
08-May-14 11:00AM  Derma Sciences, Inc. Earnings Call scheduled for 11:00 am ET today CCBN -8.31%
07:36AM  Derma Sciences affirms FY14 net sales view $92M, consensus $91.78M at theflyonthewall.com
07:35AM  Derma Sciences reports Q1 EPS (46c), consensus (32c) at theflyonthewall.com
07:30AM  Derma Sciences Reports First Quarter Financial Results Business Wire
07:07AM  Q1 2014 Derma Sciences, Inc. Earnings Release - Before Market Open CCBN
07-May-14 05:18PM  DERMA SCIENCES, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
06-May-14 11:32AM  Derma Sciences to Present at Sidoti Semiannual Micro-Cap Conference on May 9 Business Wire
02-May-14 05:02PM  Ed Quilty, CEO Of Derma Sciences, Outlines His Strategy To Build A Premier Wound Healing Company at Seeking Alpha
30-Apr-14 10:12AM  Derma Sciences to Hold First Quarter Financial Results Conference Call on May 8th Business Wire
07:00AM  3 Stocks Under $10 Making Big Moves at TheStreet
23-Apr-14 07:30AM  Derma Sciences Products to Be Featured in 10 Posters and Two Educational Programs at the SAWC Conference; Company Launches New Corporate Branding Campaign Business Wire
27-Mar-14 04:36PM  DERMA SCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
14-Mar-14 04:34PM  Derma Sciences' CEO Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
11:00AM  Derma Sciences, Inc. Earnings Call scheduled for 11:00 am ET today CCBN
07:30AM  Derma Sciences Reports Fourth Quarter Financial Results, Provides Commercial Update Including Sales Force Expansion and Progress in Launching New Placental-Derived Tissue Products Business Wire
07:07AM  Q4 2013 Derma Sciences, Inc. Earnings Release - Before Market Open CCBN
13-Mar-14 05:30PM  DERMA SCIENCES, INC. Files SEC form 10-K, Annual Report EDGAR Online
10-Mar-14 07:30AM  Derma Sciences to Hold Fourth Quarter Financial Results Conference Call on March 14th Business Wire
04-Mar-14 07:30AM  Derma Sciences to Present at the 26th Annual ROTH Conference Business Wire
28-Feb-14 10:05AM  Evaluate Biotech Stocks With Cynicism: Debjit Chattopadhyay at Seeking Alpha
19-Feb-14 01:17PM  Derma Sciences: A Not Well Followed Growth Company With Solutions For Diabetic Foot Ulcers at Seeking Alpha
05-Feb-14 03:30PM  3 Micro-Cap Stocks With Triple-Digit Upside StreetAuthority Network
31-Jan-14 06:34AM  Can Derma Sciences (DSCI) Continue to Rise? Zacks
30-Jan-14 05:43AM  Derma Sciences (DSCI) Jumps: Stock Rises 6.2% Zacks
29-Jan-14 10:17AM  Derma Sciences Closes $86 Million Underwritten Public Offering of Common Stock, Including Full Over-Allotment Business Wire +6.15%
27-Jan-14 05:30PM  DERMA SCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibit EDGAR Online
24-Jan-14 09:00AM  Derma Sciences Announces Pricing of Underwritten Public Offering of Common Stock Business Wire
23-Jan-14 04:01PM  Derma Sciences Announces Commencement of Public Offering of Common Stock Business Wire
21-Jan-14 04:27PM  DERMA SCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
17-Jan-14 05:13PM  DERMA SCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financ EDGAR Online
16-Jan-14 07:00AM  Derma Sciences Announces Record Revenues for the 2013 Fourth Quarter and Full Year, Introduces 2014 Revenue Guidance, Provides Update on DSC127 Phase 3 Clinical Trials Business Wire
14-Jan-14 10:47AM  Stocks: Insiders Buy at Opko Health and DDR; Ironwood Pharmaceuticals Sees a Sale at Minyanville
09:18AM  Derma Sciences Enters the Skin Substitute Market with Licensing Agreement for Innovative Amniotic Membrane Wound Care Products Business Wire
20-Dec-13 06:03PM  Nasdaq stocks posting largest volume increases AP
04-Dec-13 09:00AM  Derma Sciences to Present at the Oppenheimer & Co. Inc. 24th Annual Healthcare Conference Business Wire
25-Nov-13 10:45AM  INSERTING and REPLACING Derma Sciences to Participate in the 25th Annual Piper Jaffray Healthcare Conference Business Wire
14-Nov-13 05:55AM  Derma Sciences assumed with an Outperform at Oppenheimer at theflyonthewall.com
13-Nov-13 03:09PM  Derma Sciences' CEO Discusses Q3 2013 Results - Earnings Call Transcript at Seeking Alpha
11:00AM  Derma Sciences, Inc. Earnings Call scheduled for 11:00 am ET today CCBN
07:30AM  Derma Sciences Reports Third Quarter Financial Results Business Wire
07:07AM  Q3 2013 Derma Sciences, Inc. Earnings Release - Before Market Open CCBN
12-Nov-13 04:29PM  DERMA SCIENCES, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
Derma Sciences, Inc. operates as a tissue regeneration company in the wound care market. It operates in three segments: Advanced Wound Care, Traditional Wound Care, and Pharmaceutical Wound Care. The company offers Medihoney dressings for managing non-chronic and hard-to-heal wounds, such as chronic ulcers, burns, and post-operative wounds; TCC-EZ total contact cast system for patients with diabetic foot ulcers; AMNIOEXCEL for tissue repair and regeneration; and AMNIOMATRIX, which is used as a wound covering in the treatment of localized tissue defects. It also provides Xtrasorb dressings that convert fluid within the dressings to a gel and lock the exudates into the dressings; Bioguard dressings for prophylactic use in the prevention of hospital or community acquired infections through wound sites; ALGICELL AG antimicrobial dressings; and occlusive dressings, such as hydrocolloids, foams, hydrogels, alginates, additional silver antimicrobial dressings, cleansers, and DERMAGRAN products. In addition, the company offers gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages, and other compression devices; adhesive bandages and related first aid products; wound closure strips, nasal tube fasteners, and catheter fasteners; and general purpose and specialized skin care products. Further, it develops DSC127, an angiotensin analog that is in Phase III clinical trials for the treatment of diabetic foot ulcers and preclinical testing for scar reduction. The company sells its products to various health care providers, such as wound care centers, extended care facilities, acute care facilities, home health care agencies, physicians' offices, nursing homes, hospitals, and clinics through direct sales and manufacturers' representatives, independent distributors, and retail channels primarily in the United States, Canada, and the United Kingdom. Derma Sciences, Inc. was founded in 1984 and is headquartered in Princeton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WILLS STEPHEN TDirectorMay 23Option Exercise0.008,750094,821May 28 04:02 PM
STAFFORD C RICHARDDirectorMay 23Option Exercise5.608,75049,00048,223May 28 04:00 PM
Wolfenson BarrySee RemarksMay 19Buy8.795,75050,54375,085May 19 05:19 PM
Wolfenson BarrySee RemarksMay 16Buy8.795,50048,34569,335May 19 05:19 PM
QUILTY EDWARD JPresident & CEOMay 16Buy8.7010,00087,000170,172May 19 05:13 PM
CONJEEVARAM SRINIDirectorApr 21Option Exercise5.608,75049,00053,000Apr 23 04:58 PM
COLE ROBERT CSee RemarksFeb 14Option Exercise12.403,12538,75062,938Feb 19 05:40 PM
Eigner FredericExecutive VP - OperationsFeb 14Option Exercise12.403,75046,50050,300Feb 19 05:37 PM
YETTER JOHN EEVP, Finance & CFOFeb 14Option Exercise12.403,12538,75053,709Feb 19 05:35 PM
QUILTY EDWARD JPresident & CEOFeb 14Option Exercise12.406,25077,500166,043Feb 19 05:33 PM